Bionote Receives '300 Million USD Export Tower', a Commemorative Trophy from Korean MOTIE and KITA, a First for Animal Diagnostic Device Company

Bionote has received the '300 million USD Export Tower' commemorative trophy. This is the second time that Bionote has received an export achievement trophy following last year's 100 million USD export commemorative trophy and it is the first time an animal diagnostic device company has received them.Every 5th of December (Official Day of Trade), the Korean Ministry of Trade, Industry and Energy (MOTIE) and the Korean International Trade Association (KITA) holds a ceremony where they select and rewards companies that have contributed to export performance through pioneering overseas markets and creating jobs, amongst other criteria. Bionote has over 160 sales networks in over 90 countries around the world, through which Bionote exports their products such as rapid diagnostic kits, fluorescence immunoassay products (Vcheck F) and ELISA kits, amongst many others. Furthermore, Bionote has subsidiaries in key countries with large diagnostic markets such as US and China, rapidly expanding Bionote's market share.Bionote's main diagnostic device, Vcheck F, is especially well received both domestically and internationally due to its high sensitivity, achieved through the use of Europium as a fluorescence material, and its capability to quantitatively measure diverse biomarkers. Bionote also expects to grow through expansion into new markets with their Vcheck M. POC Molecular Diagnostic Device, and Vcheck C, POC Clinical Chemistry Analyzer which are planned to be launched relatively soon. 

• 2022.12.20
• Hits : 3,945

Bionote receives approval from MAFF Japan for sale of kindey disease diagnostic kit... "Will provide to 3,000 Japanese animal hospitals from next year onwards"

 DISCLAIMER: This news article is a direct translation of the original Korean article from The Stock. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.​Bionote, an in vitro diagnostic product manufacturer, announced they have completed the Japanses MAFF approval process for their 'Vcheck SDMA' kit, which is used for early screening of decreased kidney function in companion animals. Through this approval, it has become possible for Bionote to sell the 'Vcheck SDMA' kits in Japan, and Bionote has announced they will start providing it through their local Japanese partners.SDMA (Symmetric Dimethylarginine), is a amino acid that is produced during the process of breaking down proteins in the body and 90% of it is filtered by the kidney. If the kidney is not functioning properly, the SDMA does not get filtered out of the system and remains in the body. An IVD kit can be used to measure the SDMA levels in the body to screen for decreased kidney function and SDMA has less interfering factors than traditional biomarkers, with SDMA levels increasing after only 25 - 40% of damage to the kidneys.Traditional biomarkers that are used to test for kidney function, such as creatinine, is affected by factors such as whether the cat or dog in question has a lot of muscle mass and only starts to increase after around 75% of the kidney has been damaged. As such, in recent years, SDMA tests have been used more frequently for early screening of chronic kidney diseases, according to Bionote.Bionote's 'Vcheck SDMA' diagnostic kit quantitavely measures the SDMA amount in samples, using an analyzer called Vcheck F V200, quickly and with ease. Bionote also explained that when the Vcheck SDMA results were compared with lab tests, 98% of the results were in agreement. The kit only requires 100 microliters of serum or plasma (heparin) samples and the results can be confirmed after only 11 minutes, said the Bionote spokesperson.CEO of Bionote, Dr. Byung Ki Cho, said that "it has become possible for us to sell our Vcheck SDMA in Japan through this approval and registration" and that "We expect to be able to provide this product to over 3,000 animal hospitals in Japan from 2023 onwards". Bionote is currently in the process of going public in KOSPI through NH Investment & Securities and Korea Investment & Securities, at the end of the year.Link to original article: https://www.the-stock.kr/news/articleView.html?idxno=17476

• 2022.12.01
• Hits : 12,285

BIONOTE attends MEDICA, the biggest medical diagnostic exhibition in the world

 Global leader in providing biological raw materials and animal diagnostics company BIONOTE, participated in the biggest medical diagnostic exhibition in the world, MEDICA, which took place on the 14th to 18th of November in Düsseldorf, Germany.  MEDICA is a exhibition that has been taking place at Messe Düsseldorf GmbH for over 40 years and is known as the biggest exhibition in Europe for the medical diagnostic field. Even during the height of the COVID-19 pandemic last year, over 3,500 companies from 66 countries participated with 150,000 visitors from 150 countries visiting. Messe Düsseldorf has 17 halls for exhibitions, each hall for a different category of the medical field. The categories include IVD kits, diagnostic imaging, lab equipments, amongst many others. This is the first time that BIONOTE has participated in the MEDICA exhibition and they introduced their newly released Vcheck M, cutting edge POC PCR analyzer, as well as their main products, Rapid Diagnostic kits, Vcheck F and  ELISA diagnostic kits. Furthermore, they also introduced their Vcheck C, a clinical chemistry analyzer, which will be released in the first quarter of 2023. By participating in the exhibition, BIONOTE was able to introduce their excellent product concepts and future market strategies for future products, to visitors from all over the world, and to raise awareness of BIONOTE. It was a successful exhibition in terms of confirming BIONOTE's potential as a global total diagnostic solution provider.

• 2022.11.24
• Hits : 3,651